Pembrolizumab for patients with non-Hodgkin ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
Auteur(s) :
Kuruvilla, J. [Auteur]
Armand, P. [Auteur]
Hamadani, M. [Auteur]
Kline, J. [Auteur]
Moskowitz, C. H. [Auteur]
Avigan, D. [Auteur]
Brody, J. D. [Auteur]
Ribrag, V. [Auteur]
Herrera, A. F. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Kanate, A. [Auteur]
Zinzani, P. L. [Auteur]
Bitran, J. [Auteur]
Ghesquieres, H. [Auteur]
Schuster, S. J. [Auteur]
Farooqui, M. [Auteur]
Marinello, P. [Auteur]
Bartlett, N. L. [Auteur]
Armand, P. [Auteur]
Hamadani, M. [Auteur]
Kline, J. [Auteur]
Moskowitz, C. H. [Auteur]
Avigan, D. [Auteur]
Brody, J. D. [Auteur]
Ribrag, V. [Auteur]
Herrera, A. F. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Kanate, A. [Auteur]
Zinzani, P. L. [Auteur]
Bitran, J. [Auteur]
Ghesquieres, H. [Auteur]
Schuster, S. J. [Auteur]
Farooqui, M. [Auteur]
Marinello, P. [Auteur]
Bartlett, N. L. [Auteur]
Titre de la revue :
Leukemia & lymphoma
Nom court de la revue :
Leuk Lymphoma
Numéro :
64
Pagination :
130-139
Éditeur :
Taylor & Francis
Date de publication :
2022-11-19
ISSN :
1029-2403
Mot(s)-clé(s) :
Non-Hodgkin lymphoma
pembrolizumab
B-cell lymphoma
PD-L1
pembrolizumab
B-cell lymphoma
PD-L1
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation ...
Lire la suite >The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15–31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and ‘other’ NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20–61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.Lire moins >
Lire la suite >The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15–31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and ‘other’ NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20–61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.Lire moins >
Langue :
Anglais
Audience :
Internationale
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-05-25T02:22:03Z
2023-06-28T11:23:50Z
2023-06-28T11:23:50Z
Fichiers
- Pembrolizumab for patients with non Hodgkin lymphoma phase 1b KEYNOTE 013 study.pdf
- Non spécifié
- Accès libre
- Accéder au document